Akebia Therapeutics Inc expected to post a loss of 2 cents a share - Earnings Preview

Akebia Therapeutics

05/08/2025 14:35

Akebia Therapeutics Inc AKBA.OQ AKBA.O is expected to  show a rise in quarterly revenue when it reports  results on August 7 for the period ending June 30 2025

The Cambridge Massachusetts-based  company is expected to report a 8.2% increase in revenue to $47.237 million from $43.65 million a year ago, according to the mean estimate from 5 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Akebia Therapeutics Inc is for a loss of 2 cents per share.

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Akebia Therapeutics Inc is $7.00, about 46.3% above its last closing price of $3.76

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2025
-0.03
-0.04
0.03
Beat
166.7
Dec. 31 2025
-0.09
-0.08
-0.10
Missed
-25
Sep. 30 2024
-0.07
-0.06
-0.10
Missed
-57.9​
Jun. 30 2024
-0.05
-0.05
-0.04
Beat
25
​​Mar. 31 2024
-0.08
-0.08
-0.09
Missed
-17.4
Dec. 31 2023
-0.04
-0.04
0.00
Beat
100​
Sep. 30 2023
-0.07
-0.08
-0.08
Met
5.9
Jun. 30 2023
-0.02
-0.02
-0.06
Missed
-140

This summary was machine generated August 5 at 13:35 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)